Effects of WIN 55,212-2 (a synthetic cannabinoid CB1and CB2 receptor agonist) on the anticonvulsant activity of various novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice

Pharmacology Biochemistry and Behavior

Volumn 130, Issue , 2015, Pages 53-58

  Florek Luszczki, Magdalena ^a   Wlaz, Aleksandra ^b   Zagaja, Mirosław ^a   Andres Mach, Marta ^a   Kondrat Wrobel, Maria W ^b   Luszczki, JarogniewJ ^a,b  

^a INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

6 Hz psychomotor seizure model; Antiepileptic drugs; Cannabinoids; Drug interactions; WIN 55,212 2 mesylate

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANTICONVULSIVE AGENT; ETIRACETAM; GABAPENTIN; HARKOSERIDE; OXCARBAZEPINE; PREGABALIN; TIAGABINE; BENZOXAZINE DERIVATIVE; CANNABINOID RECEPTOR AGONIST; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CHIMNEY TEST; CONTROLLED STUDY; COORDINATION DISORDER; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG POTENTIATION; ELECTRODE; GRIP STRENGTH; GRIP STRENGTH TEST; MALE; MONOTHERAPY; MOTOR COORDINATION; MOUSE; MUSCLE STRENGTH; NONHUMAN; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; SEIZURE; ANIMAL; BRAIN; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; ELECTRIC SHOCK; HAND STRENGTH; METABOLISM; MOTOR PERFORMANCE; SEIZURES;

MUS;

ANIMALS; ANTICONVULSANTS; BENZOXAZINES; BRAIN; CANNABINOID RECEPTOR AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ELECTROSHOCK; HAND STRENGTH; MALE; MICE; MORPHOLINES; MOTOR SKILLS; NAPHTHALENES; SEIZURES;

EID: 84921324520     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2015.01.003     Document Type: Article

References (51)

1. Alexandre Jr V, Monteiro EA, Freitas-Lima P, Pinto KD, Velasco TR, Terra VC, et al. Addressing overtreatment in patients with refractory epilepsy at a tertiary referral centre in Brazil. Epileptic Disord 2011;13:56-60.
2. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999;58:315-48.
3. Andres-Mach M, Zolkowska D, Barcicka-Klosowska B, Haratym-Maj A, Florek-Luszczki M, Luszczki JJ. Effect of ACEA-a selective cannabinoid CB1 receptor agonist on the protective action of different antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model. Prog Neuropsychopharmacol Biol Psychiatry 2012;39:301-9.
4. Barton ME, Klein BD, Wolf HH, White HS. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 2001;47:217-27.
5. Bian F, Li Z, Offord J, Davis MD, McCormick J, Taylor CP, et al. Calcium channel alpha2- delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res 2006;23:68-80.
6. Boissier JR, Tardy J, Diverres JC. Une nouvelle méthode simple pour explorer l'action tranquilisante: le test de la cheminée. Med Exp (Basle) 1960;3:81-4.
7. Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001;60:155-63.
8. Brown WC, Schiffman DO, Swinyard EA, Goodman LS. Comparative assay of an antiepileptic drugs by psychomotor seizure test and minimal electroshock threshold test. J Pharmacol Exp Ther 1953;107:273-83.
9. Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 1998;5:534-51.
10. Degenhardt L, Hall WD. The adverse effects of cannabinoids: implications for use of medical marijuana. CMAJ 2008;178:1685-6.
11. Dooley DJ, Donovan CM, Meder WP, Whetzel SZ. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 2002;45:171-90.
12. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007;28:75-82.
13. Duncan GE, Kohn H. The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model. Epilepsy Res 2005;67:81-7.
14. Florek-Luszczki M, Wlaz A, Kondrat-Wrobel MW, Tutka P, Luszczki JJ. Effects of WIN 55,212-2 (a non-selective cannabinoid CB1 and CB 2 receptor agonist) on the protective action of various classical antiepileptic drugs in themouse 6 Hz psychomotor seizure model. J Neural Transm 2014a;121:707-15.
15. Florek-Luszczki M, Wlaz A, Kondrat-Wrobel MW, Tutka P, Luszczki JJ. Effects of WIN 55,212-2 (a non-selective cannabinoid CB and CB receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model. J Neural Transm 2014b;19:19.
16. Florek-Luszczki M, Wlaz A, Luszczki JJ. Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in themouse 6Hz psychomotor seizure model - a type II isobolographic analysis. Eur J Pharmacol 2014c;723:410-8.
17. Florek-Luszczki M, Zagaja M, Luszczki JJ. Influence ofWIN 55,212-2 on the anticonvulsant and acute neurotoxic potential of clobazam and lacosamide in the maximal electroshock-induced seizure model and chimney test in mice. Epilepsy Res 2014d; 108:1728-33.
18. Hall W, Degenhardt L. The adverse health effects of chronic cannabis use. Drug Test Anal 2014;6:39-45.
19. Hoffman AF, Macgill AM, Smith D, Oz M, Lupica CR. Species and strain differences in the expression of a novel glutamate-modulating cannabinoid receptor in the rodent hippocampus. Eur J Neurosci 2005;22:2387-91.
20. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004;1:345-58.
21. Kovacs FE, Knop T, Urbanski MJ, Freiman I, Freiman TM, Feuerstein TJ, et al. Exogenous and endogenous cannabinoids suppress inhibitory neurotransmission in the human neocortex. Neuropsychopharmacology 2012;37:1104-14.
22. Litchfield Jr JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949;96:99-113.
23. Loscher W, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res 1991;8:79-94.
24. Luszczki JJ. Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application. Naunyn Schmiedebergs Arch Pharmacol 2007;375:105-14.
25. Luszczki JJ, Czuczwar SJ. Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn Schmiedebergs Arch Pharmacol 2004;369: 434-46.
26. Luszczki JJ, Czuczwar SJ. Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis. Eur Neuropsychopharmacol 2005;15:133-42.
27. Luszczki JJ, Florek-Luszczki M. Synergistic interaction of pregabalin with the synthetic cannabinoid WIN 55,212-2 mesylate in the hot-plate test in mice: an isobolographic analysis. Pharmacol Rep 2012;64:723-32.
28. Luszczki JJ, Czuczwar M, Kis J, Krysa J, Pasztelan I, Swiader M, et al. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003a;44:1003-13.
29. Luszczki JJ, Swiader M, Parada-Turska J, Czuczwar SJ. Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsychopharmacology 2003b;28:1817-30.
30. Luszczki JJ, Andres MM, Czuczwar P, Cioczek-Czuczwar A, Wojcik-Cwikla J, Ratnaraj N, et al. Levetiracetam selectively potentiates the acute neurotoxic effects of topiramate and carbamazepine in the rotarod test in mice. Eur Neuropsychopharmacol 2005;15: 609-16.
31. Luszczki JJ, Czuczwar P, Cioczek-Czuczwar A, Czuczwar SJ. Arachidonyl-2′- chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model. Eur J Pharmacol 2006a;547:65-74.
32. Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch Pharmacol 2006b;373:169-81.
33. Luszczki JJ, Antkiewicz-Michaluk L, Czuczwar SJ. Isobolographic analysis of interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mousemaximal electroshock-induced seizuremodel. Eur J Pharmacol 2009;602:298-305.
34. Luszczki JJ, Czuczwar P, Cioczek-Czuczwar A, Dudra-Jastrzebska M, Andres-Mach M, Czuczwar SJ. Effect of arachidonyl-2?-chloroethylamide, a selective cannabinoid CB1 receptor agonist, on the protective action of the various antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Prog Neuropsychopharmacol Biol Psychiatry 2010a;34:18-25.
35. Luszczki JJ, Trojnar MK, Ratnaraj N, Patsalos PN, Czuczwar SJ. Interactions of stiripentol with clobazam and valproate in the mouse maximal electroshock-induced seizure model. Epilepsy Res 2010b;90:188-98.
36. Luszczki JJ, Andres-Mach M, Barcicka-Klosowska B, Florek-Luszczki M, Haratym-Maj A, Czuczwar SJ. Effects ofWIN 55,212-2 mesylate (a synthetic cannabinoid) on the protective action of clonazepam, ethosuximide, phenobarbital and valproate against pentylenetetrazole-induced clonic seizures in mice. Prog Neuropsychopharmacol Biol Psychiatry 2011a;35:1870-6.
37. Luszczki JJ, Misiuta-Krzesinska M, Florek M, Tutka P, Czuczwar SJ. Synthetic cannabinoid WIN 55,212-2 mesylate enhances the protective action of four classical antiepileptic drugs against maximal electroshock-induced seizures in mice. Pharmacol Biochem Behav 2011b;98:261-7.
38. Luszczki JJ, Wlaz A, Karwan S, Florek-Luszczki M, Czuczwar SJ. Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice. Eur J Pharmacol 2013;720:247-54.
39. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004;101:9861-6.
40. Meyer OA, Tilson HA, Byrd WC, Riley MT. A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav Toxicol 1979;1:233-6.
41. Naderi N, Aziz Ahari F, Shafaghi B, Najarkolaei AH, Motamedi F. Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice. J Neural Transm 2008;115:1501-11.
42. Nemeth B, Ledent C, Freund TF, Hajos N. CB1 receptor-dependent and -independent inhibition of excitatory postsynaptic currents in the hippocampus byWIN 55,212-2. Neuropharmacology 2008;54:51-7.
43. Perucca E, Kwan P. Overtreatment in epilepsy: how it occurs and how it can be avoided. CNS Drugs 2005;19:897-908.
44. Ratnaraj N, Patsalos PN. A high-performance liquid chromatography micromethod for the simultaneous determination of vigabatrin and gabapentin in serum. Ther DrugMonit 1998;20:430-4.
45. Ratnaraj N, Doheny HC, Patsalos PN. A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography. Ther Drug Monit 1996;18:154-7.
46. Rowley NM, White HS. Comparative anticonvulsant efficacy in the corneal kindledmouse model of partial epilepsy: correlation with other seizure and epilepsy models. Epilepsy Res 2010;92:163-9.
47. Shandra A, Shandra P, Kaschenko O, Matagne A, Stohr T. Synergism of lacosamide with established antiepileptic drugs in the 6-Hz seizure model in mice. Epilepsia 2013;54:1167-75.
48. Smith M, Wilcox KS, White HS. Discovery of antiepileptic drugs. Neurotherapeutics 2007; 4:12-7.
49. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29:233-49.
50. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007;73:137-50.
51. Wojda E, Wlaz A, Patsalos PN, Luszczki JJ. Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model. Epilepsy Res 2009;86:163-74.